LIPOSOMAL CURCUMIN
500MG CAPSULES
PEMBROLIZUMAB
Restores T-cell mediated anti-tumor immunity
Approved for PD-L1 positive recurrent/metastatic cervical cancer
Helps the immune system recognize and attack cancer cells
Used after progression on chemotherapy or as per approved indications
CURSOMAL
May influence HPV E6/E7 oncoproteins
May promote apoptosis in cervical cancer cells
Supports antioxidant pathways
Supports immune-related pathways
Supports immune-related pathways
CURSOMAL® (Liposomal Curcumin) may provide adjunctive supportive benefits alongside PEMBROLIZUMAB by supporting antioxidant and immune-related pathways, promoting apoptosis, and supporting overall treatment goals and quality of life, based on clinical judgment and individual patient needs.
PEMBROLIZUMAB
Approved for MSI-H/dMMR colorectal cancer.
Strong immune activation in mutation-rich cancers.
Restores immune surveillance by blocking PD-1.
Can provide durable responses with long-term survival benefit.
CURSOMAL
May Modulate Wnt/β-Catenin Pathway
May Modulate p53 Pathway
May Reduce Inflammatory Signaling
Supports Tumor Microenvironment
May Support Treatment Response
CURSOMAL® (Liposomal Curcumin) may be considered as an ADJUVANT SUPPORTIVE OPTION alongside PEMBROLIZUMAB by supporting Wnt/β-Catenin and p53 pathway modulation, reducing inflammatory signaling, and supporting the tumor microenvironment and treatment response, based on clinical judgment and individual patient needs.
PEMBROLIZUMAB
Approved for Mismatch Repair-Deficient (MSI-H/dMMR) Tumors
Reactivates Anti-tumor Immunity
Restores Immune Surveillance
Provides an Option After Prior Therapy
CURSOMAL
May Inhibit PI3K/Akt/mTOR Signaling
May Reduce Inflammatory Responses
May Reduce Hormone-driven Proliferation
May Support Regulation of Abnormal Cell Growth
May Support Overall Treatment Response
CURSOMAL® (Liposomal Curcumin) may be considered as an ADJUVANT SUPPORTIVE OPTION alongside PEMBROLIZUMAB to support PI3K/Akt/mTOR pathway modulation, reduce inflammatory responses, support regulation of abnormal cell growth, and contribute to overall treatment goals, based on clinical judgment and individual patient needs.
PEMBROLIZUMAB
Used for PD-L1 Positive Advanced Disease
Enhances Immune-Mediated Tumor Recognition
Restores Immune Surveillance
Often Combined with Chemotherapy
CURSOMAL
May Inhibit NF-κB Pathway
May Inhibit COX-2 Pathway
May Reduce Inflammation
May Help Inhibit Tumor Progression
Supports Overall Treatment
CURSOMAL® (Liposomal Curcumin) may be considered as an ADJUVANT SUPPORTIVE OPTION alongside PEMBROLIZUMAB to support NF-κB and COX-2 pathway modulation, reduce inflammatory responses, and support overall treatment goals, based on clinical judgment and individual patient needs.
PEMBROLIZUMAB
Used for PD-L1 Positive Advanced Disease
Restores Immune Surveillance
Enhances Immune Response
Used in Combination with Chemotherapy
CURSOMAL
May Inhibit STAT3 Signaling
May Inhibit Notch Signaling
May Reduce Tumor Cell Proliferation
Supports Tumor Microenvironment
May Support Treatment Response
CURSOMAL® (Liposomal Curcumin) may be considered as an ADJUVANT SUPPORTIVE OPTION alongside PEMBROLIZUMAB to support STAT3 and Notch pathway modulation, reduce tumor-cell proliferation, and support the tumor microenvironment and treatment response, based on clinical judgment and individual patient needs.
PEMBROLIZUMAB
Approved for Recurrent / Metastatic HNSCC
Blocks PD-1 to Enhance T-cell Function
Restores Immune Attack
Used After Platinum Therapy
CURSOMAL
Modulates EGFR Pathway
Modulates COX-2 Pathway
Reduces Tumor-Associated Inflammation
Inhibits Cell Proliferation
Supports Response to Therapies
CURSOMAL® (Liposomal Curcumin) may be considered as an ADJUVANT SUPPORTIVE OPTION alongside PEMBROLIZUMAB to support EGFR/COX-2 pathway modulation, help manage tumor-associated inflammation, support therapeutic response, and promote overall treatment goals and quality of life, based on clinical judgment and individual patient needs.
PEMBROLIZUMAB
Used in Combination Therapy
Enhances Immune Response
Supports Immune Control
Improves Outcomes
CURSOMAL
May Inhibit STAT3 Pathway
May Inhibit NF-κB Pathway
May Inhibit VEGF Pathway
Supports Liver Health
May Reduce Inflammation
May Enhance Treatment Response
CURSOMAL® (Liposomal Curcumin) may be considered as an ADJUVANT SUPPORTIVE OPTION alongside PEMBROLIZUMAB to potentially support STAT3, NF-κB, and VEGF pathway modulation, help maintain liver health, reduce inflammation, and support treatment response, based on clinical judgment and individual patient needs.
PEMBROLIZUMAB
Restores Immune Attack
Targets Melanoma Cells
First-Line Immunotherapy
Durable Responses
CURSOMAL
Inhibits Melanoma Cell Proliferation
Anti-Angiogenic Activity
Antioxidant Support
Anti-Inflammatory Activity
Adjunct Nutritional Support
CURSOMAL® (Liposomal Curcumin) may be considered as an ADJUVANT SUPPORTIVE OPTION alongside PEMBROLIZUMAB to potentially support melanoma-focused treatment goals through anti-proliferative, anti-angiogenic, antioxidant, and anti-inflammatory effects, while providing adjunct nutritional support, based on clinical judgment and individual patient needs.
PEMBROLIZUMAB
Restores T-cell Function
Targets Tumor Cells
Approved for NSCLC
Improves Survival Outcomes
CURSOMAL
Modulates Key Signaling Pathways
Supports Immune Function
Anti-inflammatory & Antioxidant
Supports Anti-tumor Activity
May Complement Immunotherapy
CURSOMAL® (Liposomal Curcumin) may be considered as an ADJUVANT SUPPORTIVE OPTION alongside PEMBROLIZUMAB to potentially support immune function, modulate key signaling pathways, and provide anti-inflammatory, antioxidant, and adjunct anti-tumor support, based on clinical judgment and individual patient needs.
PEMBROLIZUMAB
First-Line (in Combination Therapy)
Enhances Immune Response
Targets RCC Cells
Improves Survival
CURSOMAL
May Inhibit VEGF Pathways
May Reduce Inflammatory Signaling
Supports Antioxidant Defenses
May Inhibit Tumor Growth
Supports Response to Therapy
CURSOMAL® (Liposomal Curcumin) may be considered as an ADJUVANT SUPPORTIVE OPTION alongside PEMBROLIZUMAB to potentially support VEGF-pathway modulation, help reduce inflammatory signaling, maintain antioxidant defenses, and provide adjunct support for tumor-growth control and treatment response, based on clinical judgment and individual patient needs.
PEMBROLIZUMAB
Used with Chemotherapy
Enhances Immune Function
Targets TNBC Cells
Improves Outcomes
CURSOMAL
Suppresses NF-κB Signaling
Inhibits Wnt/β-catenin Pathway
Targets Cancer Stem Cells
Reduces Inflammatory Signaling
Supports Treatment Response
CURSOMAL® (Liposomal Curcumin) may be considered as an ADJUVANT SUPPORTIVE OPTION alongside PEMBROLIZUMAB to potentially support NF-κB and Wnt/β-catenin pathway modulation, provide adjunct support against cancer stem-cell activity, reduce inflammatory signaling, and support treatment response, based on clinical judgment and individual patient needs.
